scholarly journals Evolvement of microRNAs as Therapeutic Targets for Malignant Gliomas

10.5772/52672 ◽  
2013 ◽  
Author(s):  
Sihan Wu ◽  
Wenbo Zhu ◽  
Guangmei Y
Keyword(s):  
Malignant Gliomas ◽  
Therapeutic Targets

scholarly journals Fusion Genes Altered in Adult Malignant Gliomas

2021 ◽  
Vol 12 ◽  
Author(s):  
Gan You ◽  
Xing Fan ◽  
Huimin Hu ◽  
Tao Jiang ◽  
Clark C. Chen
Keyword(s):  
Genetic Background ◽  
Molecular Genetic ◽  
Malignant Gliomas ◽  
Therapeutic Targets ◽  
High Grade ◽  
Gene Fusions ◽  
Fusion Genes ◽  
High Grade Gliomas ◽  
The Many

Malignant gliomas are highly heterogeneous brain tumors in molecular genetic background. Despite the many recent advances in the understanding of this disease, patients with adult high-grade gliomas retain a notoriously poor prognosis. Fusions involving oncogenes have been reported in gliomas and may serve as novel therapeutic targets to date. Understanding the gene fusions and how they regulate oncogenesis and malignant progression will contribute to explore new approaches for personalized treatment. By now, studies on gene fusions in gliomas remain limited. However, some current clinical trials targeting fusion genes have presented exciting preliminary findings. The aim of this review is to summarize all the reported fusion genes in high-grade gliomas so far, discuss the characterization of some of the most popular gene fusions occurring in malignant gliomas, as well as their function in tumorigenesis, and the underlying clinical implication as therapeutic targets.

scholarly journals Molecular Therapeutic Targets for Glioma Angiogenesis

2010 ◽  
Vol 2010 ◽  
pp. 1-11 ◽  
Author(s):  
Shingo Takano ◽  
Toshiharu Yamashita ◽  
Osamu Ohneda
Keyword(s):  
Endothelial Cells ◽  
Antiangiogenic Therapy ◽  
Malignant Gliomas ◽  
Therapeutic Targets ◽  
Molecular Targets ◽  
Endogenous Inhibitors ◽  
Molecular Therapeutic ◽  
Molecular Therapeutic Targets ◽  
The Brain ◽  
Induced Proteins

Due to the prominent angiogenesis that occurs in malignant glioma, antiangiogenic therapy has been attempted. There have been several molecular targets that are specific to malignant gliomas, as well as more broadly in systemic cancers. In this review, I will focus on some topics related to molecular therapeutic targets for glioma angiogenesis. First, important angiogenic factors that could be considered molecular targets are VEGF, VEGF-induced proteins on endothelial cells, tissue factor, osteopontin, integrin, and thymidine phosphorylase as well as endogenous inhibitors, soluble Flt1, and thrombospondin 1. Second, hypoxic areas are also decreased by metronomic CPT11 treatment as well as temozolomide. Third, glioma-derived endothelial cells that are genetically and functionally distinct from normal endothelial cells should be targeted, for example, with SDF-1 and CXCR7 chemokine. Fourth, endothelial progenitor cells (EPCs) likely contribute towards glioma angiogenesis in the brain and could be useful as a drug delivery tool. Finally, blockade of delta-like 4 (Dll4) results in a nonfunctioning vasculature and could be another important target distinct from VEGF.

scholarly journals Common Molecular Alterations in Canine Oligodendroglioma and Human Malignant Gliomas and Potential Novel Therapeutic Targets

2019 ◽  
Vol 9 ◽  
Author(s):  
Dana Mitchell ◽  
Sreenivasulu Chintala ◽  
Kaleigh Fetcko ◽  
Mario Henriquez ◽  
Brij N. Tewari ◽  
...  
Keyword(s):  
Malignant Gliomas ◽  
Therapeutic Targets ◽  
Molecular Alterations ◽  
Novel Therapeutic

Shared therapeutic targets in genetic skeletal diseases

2015 ◽  
Author(s):  
Michael D Briggs ◽  
Katarzyna A Pirog ◽  
Peter A Bell
Keyword(s):  
Therapeutic Targets
Sign in / Sign up

Export Citation Format

Share Document